Please provide your email address to receive an email when new articles are posted on . A 23-year-old female with no significant medical history developed a headache. On the evening of the following ...
New York, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA ...
Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population Sixty-five eligible adults with newly diagnosed ...
DUBLIN--(BUSINESS WIRE)--The "Gliosarcoma Ongoing Global Clinical Trials Analysis and Outlook" report has been added to ResearchAndMarkets.com's offering. Gliosarcoma ongoing clinical trials report ...
April 30, 2012 (Miami, Florida) — The use of bevacizumab to treat recurrent glioblastoma multiforme (GBM) may raise the risk for secondary gliosarcoma (GS). Bevacizumab (Avastin, Genentech), an ...
Few reported cases of gliosarcomas or glioblastomas with epithelial-like areas exist. Most cases were originally diagnosed as metastatic carcinoma. Focal expression of glial fibrillary acidic protein ...
Dublin, April 02, 2026 (GLOBE NEWSWIRE)-- The "Gliosarcoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights, covering global market ...
Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population Sixty-five eligible adults with newly diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results